IntelGenx Provides Update on Research Collaboration Evaluating Montelukast VersaFilm® for the Treatment of Parkinson’s Disease
July 25 2023 - 8:00AM
IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or
"IntelGenx") today announced the execution of a Research Grant
Agreement with Karolinska University Hospital and that the
manufacturing of both active and placebo films are underway in
preparation for a planned multicentre, randomized, double-blind,
placebo-controlled clinical study (the “Study”) to investigate the
use of IntelGenx’s Montelukast VersaFilm® for the treatment of
Parkinson’s Disease (“PD”).
The Study will be conducted at the Karolinska
University Hospital under IntelGenx’s previously announced research
collaboration with Per Svenningsson, MD, PhD, who will serve as the
Study’s Principal Investigator. Dr. Svenningsson – a Professor of
Clinical Neuroscience who investigates the pathogenic mechanisms of
PD – previously conducted a clinical study utilizing the tablet
form of Montelukast for the treatment of PD, where 2 tablets of 10
mg Montelukast were administered twice daily, for a total daily
dose of 40 mg.
“Prof. Svenningsson’s interest in evaluating
Montelukast VersaFilm® for the treatment of PD reflects his
confidence in the drug’s therapeutic potential, which is based on
findings from his earlier Montelukast tablet study, the higher
bioavailability of our film formulation, as well as the need for a
more convenient dosing method,” said Dwight Gorham, IntelGenx’s
CEO. “As the planned study will assess Montelukast in doses
exceeding 40 mg, Montelukast VersaFilm® offers study participants
an attractive dosing alternative to tablets, which would require
administration of multiple tablets several times per day.”
Prof. Svenningsson will sponsor the study
through a 20 million Swedish Crowns grant (approx. $2 million USD)
awarded by the Swedish Research Council, Sweden’s largest
governmental research funding body. Upon completion of the Study,
IntelGenx will have the option to acquire the developed
intellectual property rights and study data for a predetermined low
five-digit amount and use the findings to further develop its
Montelukast VersaFilm® program for PD treatment.
About IntelGenx
IntelGenx is a leading drug delivery company
focused on the development and manufacturing of pharmaceutical
films.
IntelGenx’s superior film technologies,
including VersaFilm®, DisinteQ™, VetaFilm® and transdermal
VevaDerm™, allow for next generation pharmaceutical products that
address unmet medical needs. IntelGenx’s innovative product
pipeline offers significant benefits to patients and physicians for
many therapeutic conditions.
IntelGenx's highly skilled team provides
comprehensive pharmaceuticals services to pharmaceutical partners,
including R&D, analytical method development, clinical
monitoring, IP and regulatory services. IntelGenx's
state-of-the-art manufacturing facility offers full service by
providing lab-scale to pilot- and commercial-scale production. For
more information, visit www.intelgenx.com.
Forward-Looking Information and
Statements
This document may contain forward-looking
information about IntelGenx's operating results and business
prospects that involve substantial risks and uncertainties.
Statements that are not purely historical are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and Section 27A of the Securities
Act of 1933, as amended. These statements include, but are not
limited to, statements about IntelGenx's plans, objectives,
expectations, strategies, intentions or other characterizations of
future events or circumstances and are generally identified by the
words "may," "expects," "anticipates," "intends," "plans,"
"believes," "seeks," "estimates," "could," "would," and similar
expressions. All forward looking statements are expressly qualified
in their entirety by this cautionary statement. Because these
forward-looking statements are subject to a number of risks and
uncertainties, IntelGenx's actual results could differ materially
from those expressed or implied by these forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, those discussed under
the heading "Risk Factors" in IntelGenx's annual report on Form
10-K, filed with the United States Securities and Exchange
Commission and available at www.sec.gov, and also filed with
Canadian securities regulatory authorities at www.sedar.com.
IntelGenx assumes no obligation to update any such forward-looking
statements.
Source: IntelGenx Technologies Corp.
For IntelGenx:
Stephen KilmerInvestor Relations(647)
872-4849stephen@kilmerlucas.com
Or
Andre Godin, CPA, CAPresident and CFOIntelGenx Corp.(514)
331-7440 ext 203andre@intelgenx.com
Intelgenx Technologies (TSX:IGX)
Historical Stock Chart
From Apr 2024 to May 2024
Intelgenx Technologies (TSX:IGX)
Historical Stock Chart
From May 2023 to May 2024